WO2025202971 - KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
National phase entry is expected:
Publication Number
WO/2025/202971
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053263
International Filing Date
27.03.2025
Title **
[English]
KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
[French]
INHIBITEUR DE KRAS G12C DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DU CANCER DU POUMON NON À PETITES CELLULES
Applicants **
NOVARTIS AG
Inventors
BITTON, Rafael Caparica
CUI, Xiaoming
LOBETTI BODONI, Chiara
YOVINE, Alejandro Javier
Priority Data
63/570,545
27.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2317 | |
| EPO | Filing, Examination, Granting | 12404 | |
| Japan | Filing, Examination, Granting | 2399 | |
| South Korea | Filing, Examination, Granting | 2573 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
25,633
Contact Us
Abstract[English]
The present invention relates to a method of treating non-small cell lung cancer (NSCLC) which harbors a KRAS G12C mutation, wherein the method comprises the administration of KRAS G12C inhibitor 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (Compound A), or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a therapeutically effective amount of pembrolizumab; in particular the present invention relates to a method of treating NSCLC wherein the NSCLC expresses at least 1% PD-L1 according to the tumor proportion score (TPS), more particularly the NSCLC expresses at least 50% PD-L1 according to the tumor proportion score (TPS).[French]
La présente invention concerne une méthode de traitement du cancer du poumon non à petites cellules (NSCLC) qui héberge une mutation KRAS G12C. La méthode consiste à administrer un inhibiteur de KRAS G12C, 1-6-[(4M)-4-(5-chloro-6-méthyl-1H-indazol-4-yl)-5-méthyl-3-(1-méthyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3,3]heptan-2-yl}prop-2-en-1-one (composé A), ou un sel, solvate ou hydrate pharmaceutiquement acceptable de celui-ci, et une quantité thérapeutiquement efficace de pembrolizumab. En particulier, la présente invention concerne une méthode de traitement du NSCLC, le NSCLC exprimant au moins 1 % de PD-L1 selon le score de proportion tumorale (TPS), plus particulièrement le NSCLC exprimant au moins 50 % de PD-L1 selon le score de proportion tumorale (TPS).